

Codexis Pipeline Snapshot

June 30th, 2020

CODEXIS[®]



Codexis Pipeline Snapshot – June 30th 2020

Pipeline Project or Product Category		Pre-Commercial Programs		Commercial Sustaining Revenues <i>Product Sales and/or Licensing</i>	Pipeline Total <i>06/30/2020</i>	<i>vs. prior pipeline</i> 6/30/2019
		<i>Codexis Self-funded</i>	<i>Customer Partnered</i>			
Performance Enzymes	Pharma Manufacturing:		24	11	35	+5
	<i>Clinical Phases II or III</i>		19	n/a	19	+4
	<i>Patented On-the-Market Drugs</i>		1	5	6	+2
	<i>Generic On-the-Market Drugs</i>		4	6	10	-1
	Non-Pharma Products & Processes:	7	6	3	16	+4
	<i>Life Sciences</i>	5	2	1	8	+3
	<i>Food, Feed & Nutrition</i>	1	3	2	6	-
	<i>Industrial Enzymes</i>	1	1		2	+1
BioTx	Discovery and Development of Novel Biotherapeutics	6	8		14	+4
Pipeline Total as of June 30, 2020		13	38	14	65	+13

vs prior pipeline

+1	+9	+3	+13
----	----	----	-----

GUIDE TO THE PIPELINE SNAPSHOT

Row Headers

- Independent categories in which Codexis is creating high value protein innovations.
- Excludes biocatalysts for small molecule pharmaceuticals through Phase 1 development as they are too numerous, unclear re: stage of development and collectively of minimal revenue impact.

Column Headers


- **ALL Projects are Codexis Driven** – projects where protein innovations have been or are being created by Codexis teams.
- **Pre-commercial** are projects or products that have yet to be fully commercialized by Codexis and/or our customers.
- **Commercial** are projects or products that have been fully commercialized by both Codexis and our customers and are sources of sustained revenue for Codexis.

For a Project or Product to register in our Pipeline


- It must have generated > \$100,000 in revenue and/or incurred > \$100,000 in costs over the prior 2 years.

Strong and Growing Opportunity Pipeline

Total Pipeline Growth: 2016-2020



Pipeline Distribution and Growth by Segment: 2016-2020



Contact Us

John Nicols

President & Chief Executive Officer

john.nicols@codexis.com

(650) 421-2388

Ross Taylor

Sr. Vice President & Chief Financial Officer

ross.taylor@codexis.com

(650) 421-8112

Stephanie Marks / Natallia Clancy

Argot Partners

Codexis@argotpartners.com

(212) 600-1902

200 Penobscot Drive
Redwood City, CA 94063
USA

Nasdaq: **CDXS**

www.codexis.com